Amgen Inc. Stock (US0311621009): Dow component under pressure after recent pullback

Amgen shares, a heavyweight in the Dow Jones and biotech space, are back in focus after a recent pullback on the Nasdaq. Here is how the stock has been trading lately and where it stands versus key U.S. peers.

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 11, 2026 at 6:04 PM ET. Details in the imprint.

Amgen Inc. is back in focus for U.S. investors after a notable pullback in recent Nasdaq trading, which left the large-cap biotech stock among the weaker names in the Dow Jones Industrial Average in the latest session with biotech data available as of June 10, 2026. While the move does not reflect any single fresh company-specific headline, it highlights how the stock is currently trading against a backdrop of sector volatility and broader index swings.

How Amgen shares have been trading recently

Recent U.S. market data from Investing.com show that Amgen shares closed at about $337.73 in the latest session with complete quotes available, marking a decline of roughly 1.98 percent on June 10, 2026. By comparison, a separate intraday report from finanzen.ch cited Amgen among the strongest names in the Dow Jones at one point, with the stock trading around $344.65 and up about 2.05 percent on the day in that snapshot. Taken together, these data points underscore that Amgen has seen meaningful intraday and day-to-day swings over recent sessions.

In European trading, the stock’s German listing on Xetra was recently quoted near 288.35 euros, up about 0.51 percent on that day, while the U.S. listing around the same period was indicated at about $335.03, down roughly 0.44 percent in that snapshot. The divergence between the modest uptick in the euro-based quote and the small decline in the U.S. quote reflects normal intraday currency and timing effects rather than a structural difference in how investors view the company across markets.

Amgen is a constituent of the Dow Jones Industrial Average, which means movements in its share price can influence the headline index and, conversely, that broad Dow sentiment can feed back into trading in the stock. The company is also part of major U.S. benchmarks for large-cap equities and the biotech and pharmaceuticals space, so shifts in sector exchange-traded funds and index allocations can translate into incremental buying or selling pressure on the shares. In this context, the recent pullback aligns with a session in which several big health care and biotech names also saw declines, according to the peer overview from MarketScreener.

On a sector comparison basis, MarketScreener’s overview of large health care names shows Amgen down about 1.98 percent on the referenced day, alongside Gilead Sciences down about 3.20 percent and Pfizer down around 0.39 percent, with the average move across the referenced group at roughly negative 0.36 percent. This indicates that Amgen’s drop was larger than the average for that selected peer basket but not an outlier for the biotech-heavy segment of large-cap pharma and life sciences companies.

Where Amgen stands among U.S. biotech and pharma peers

From a competitive perspective, Amgen shares trade in a crowded space that includes big-cap biotech firms and diversified pharmaceutical companies, many of which are also components of major U.S. indexes and health care ETFs. According to MarketScreener’s sector snapshot, Amgen, Gilead Sciences, and Pfizer all moved lower in the referenced session, but Amgen’s roughly 1.98 percent decline fell between the steeper slide at Gilead and the smaller dip at Pfizer. This kind of relative move is consistent with Amgen’s profile as a large, diversified biotech name with strong legacy products and meaningful exposure to newer therapeutic areas.

While the latest data do not show a single specific news headline on June 11, 2026 that would explain the short-term volatility, Amgen has been active on the regulatory front in recent months. For example, an EQS release cited by FinanzNachrichten reports that the European Commission granted approval for Imdylltra, an Amgen therapy, in the European Union, which adds another product to the company’s international portfolio and underscores its ongoing pipeline execution. Regulatory updates like this can shape investor expectations on medium-term revenue trends, even if they do not always move the stock on the specific day of the announcement.

Amgen’s position as a Dow component differentiates it from some pure-play biotech peers that trade on the Nasdaq Composite without inclusion in the price-weighted Dow Jones Industrial Average. This inclusion typically increases visibility among U.S. retail investors who follow Dow stocks, especially when media outlets highlight daily gainers and decliners. In an earlier session referenced by finanzen.ch, Amgen was among the strongest Dow constituents with a gain of about 2.05 percent at a price of $344.65, showing that the stock can quickly shift from leader to laggard depending on daily flows and sentiment swings.

Sector data compiled around Novo Nordisk, another major health-related name, show that Amgen’s negative move of roughly 1.98 percent on the referenced day placed it in a group of health care names that were generally under pressure, even as broader market conditions remained relatively constructive in some sessions. For investors who track relative performance, this may suggest that recent weakness is at least partially sector-driven, rather than tied to an isolated problem unique to Amgen.

Looking at global trading, the fact that Amgen’s Xetra quote in euros and the U.S. dollar price on Nasdaq can move in slightly different directions on the same calendar day underlines how local investor flows, time zones, and currency dynamics shape the intraday pattern for large, internationally traded U.S. stocks. Over longer horizons, however, the euro and dollar quotes tend to reflect the same underlying valuation, adjusted for exchange rates and local factors such as liquidity and trading hours.

For U.S. retail investors, the main line of sight remains the Nasdaq listing under the AMGN ticker, with quotes in U.S. dollars and inclusion in widely followed indices such as the Dow Jones Industrial Average. As usual, liquidity and index membership can amplify intraday volatility, particularly around sector rotation days when flows into and out of health care ETFs and mutual funds are elevated.

Overall, the latest trading data suggest that Amgen’s recent pullback is broadly consistent with a period of increased volatility in large-cap biotech and health care stocks, rather than a sharp, idiosyncratic dislocation in the name. Investors watching the stock may therefore want to place the short-term move in the context of the company’s established role in major U.S. indexes, its ongoing regulatory and pipeline activities, and the broader dynamics of the biotech and pharmaceuticals sector.

Amgen Inc. at a glance

• Name: Amgen Inc.
• Industry: Biotechnology and pharmaceuticals
• Headquarters: Thousand Oaks, California, United States
• Core markets: United States, Europe, and other global biopharma markets
• Revenue drivers: Biologic therapies and medicines across oncology, inflammation, cardiovascular disease, and other serious conditions
• Listing: Nasdaq, ticker symbol AMGN; component of the Dow Jones Industrial Average
• Trading currency: U.S. dollars (USD)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.